Cancer Advisor

Medically Reviewed by: OneDayMD Editorial Team | Written by:     Dr Frank Yap, MD | Last Updated: August 8, 2026 Quick Answer The most consequential 2026 cancer breakthrough is daraxonrasib , an oral RAS(ON) inhibitor that nearly doubled overall survival in previously treated metastatic pancreatic cancer in the phase 3 RASolute 302 trial presented at ASCO 2026. Other major advances include the OPTIMA trial , showing many high-risk breast cancer patients can safely skip chemotherapy after genomic testing; the bispecific antibody ivonescimab , which outperformed standard immunotherapy in squamous lung cancer; continued expansion of CAR-T and cell therapies into solid tumors; and growing, evidence-tiered interest in repurposed drugs and metabolic approaches as complementary strategies. AACR 2026 and ASCO 2026 both emphasized that progress is driven by combining precision diagnostics, immunotherapy, and targeted agents — not a single cure. Cancer remains ...

OneDayMD Cancer Academy A patient-first evidence guide to colon and rectal cancer — from the first abnormal test and diagnosis through staging, molecular profiling, treatment, treatment resistance, monitoring, clinical trials and survivorship. The goal is not to tell you what treatment to take. The goal is to help you understand the questions, tests, biomarkers and treatment concepts that can help you have better-informed conversations with your oncology team. Start With Your Questions Find Your Journey Understand Biomarkers Important: This page is an educational resource, not medical advice, diagnosis or individualized treatment guidance. Colorectal cancer treatment depends on factors including the cancer's location, stage, pathology, molecular characteristics, previous treatment, overall health and patient preferences. Treatment decisions should be made with qualified healthcare professionals. ...